Where and how does semaglutide fit in the treatment of type 2 diabetes?- A case-based discussion

Novo Nordisk A/S |

Chair: Filip Knop (DNK)

11:45 – 11:50Welcome and Introduction
Overview of semaglutide, PIONEER and SUSTAIN trials
Filip Knop (DNK)
11:50 – 12:00Case based discussions on clinical evidenceFilip Knop (DNK)
Melanie Davies (UK)
12:00 – 12:05Patient-centric practicalitiesFilip Knop (DNK)
Melanie Davies (UK)
12:05 – 12:15Panel discussion, Q&A and closing remarksFilip Knop (DNK)
Melanie Davies (UK)